Age-related macular degeneration by Grech Hardie, John
age-related Macular Degeneration (AMD) is a degenerative condition affecting the macular area of the retina. Those affected are usually over the age of 50 years and AMD is the 
leading cause of blindness over this age in the Western world. 
It results in distortion or loss of central sharp vision making 
it difficult to view the object of interest and to carry out close 
work, to read and write, to recognise faces and to drive although 
enough peripheral vision remains to allow other activities of 
daily life. Figure 1 compares a normal vision (a) and the vision 
in advanced AMD (b).
causes and risk factors
•	 Ageing: approximately 10% of people aged 66 to 74 show 
findings of macular degeneration. The prevalence increases 
to 30% in the 75 to 85 year age group.
•	 Family history: the risk of developing macular degeneration 
is 50% for those with a relative with macular degeneration 
versus 12% for those with no family history.
•	 Genetics: changes in several genes, the best studied of which 
are those involved with the complement system, have been 
implicated as possible risk factors in AMD.
•	 Hypertension.
•	 Cholesterol: elevated cholesterol may increase the risk of 
AMD.
•	 Obesity: a risk factor especially among men.
•	 Race: AMD is more common in Caucasians than in people 
of African descent.
•	 Exposure to sunlight especially blue light: there is 
conflicting evidence about this with some studies showing a 
relationship and others not.
•	 Smoking: tobacco smokers show a 2-3 times risk of AMD 
compared to non-smokers.
AMD is a gradually progressive disease and can pass from 
early AMD to geographic atrophy and/or neovascular AMD. 
Early AMD and geographic atrophy are the non-vascular or dry 
types and account for 90% of AMD while the neovascular or wet 
type accounts for 90% of blind registrations from AMD.
(a) early amd
Early AMD is usually asymptomatic with the appearance of 
Drusen of variable size and shape and focal hypo-pigmentation/
hyper-pigmentation of the macular area (figure 2). Drusen 
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Figure 1: Comparison between a normal vision (A) and vision 
in advanced AMD (B)
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are yellowish deposits or accumulations of PAS-positive 
amorphous material in Bruch’s membrane under the retina 
while the pigmentary changes correspond to retinal pigment 
epithelium and photoreceptor loss.
Treatment at this stage involves:
•	 Stopping smoking: this is probably the most important 
modifiable factor.
•	 Diet and anti-oxidant vitamin supplementation: the 
Age-related Eye Disease studies (AREDS and AREDS2) 
showed that an anti-oxidant vitamin combination 
(500mg Vit C, 400IU Vit E, 15 mg beta-carotene, 80mg 
Zinc and 2mg Copper) had a moderate protective effect 
(25% decrease in the risk of developing late AMD) 
on the fellow eye of patients with vision loss from 
moderate to late AMD. Beta-carotene is contra-indicated 
in smokers as it increases the risk of lung cancer. 
AREDS2 showed that it can be substituted with 10mg 
lutein and 2mg zeaxanthin with no loss of effect and 
modern drug formulations make use of this fact. Many 
ophthalmologists place patients on these supplements 
even at an early stage of the disease.
•	 Monitoring of vision using an Amsler grid chart and 
yearly, or as required, ophthalmic review. An Amsler 
grid examines a person’s central visual field. In the test, 
done serially at home, the subject looks at the small 
dot at the centre of the grid with each eye separately. 
The appearance of wavy or missing lines is indicative 
of macular disease and should prompt the patient to 
seek ophthalmic review. The test is particularly useful 
in monitoring the fellow unaffected eye of a patient 
with advanced AMD in the other eye. The chart can be 
easily downloaded from the Internet. Figure 3 depicts an 
Amsler grid chart in advanced AMD. 
(b) geographic atrophy
Together with Drusen, this shows slowly enlarging 
sharply demarcated areas of atrophy of the retina with 
exposure of the underlying choroidal vessels (figure 4). 
Treatment at this stage is the same as for early AMD as 
well as the use of low-vision aides such as magnifying lenses 
and computer screen readers which enlarge reading material.
(c) neovascular or exudative amd
This typically presents with an acute change in central 
vision such as distortion (metamorphopsia) or a blind 
spot. The responsible lesion is a growth of choroidal 
neovascularisation (CNV) from the choroid through 
Bruch’s membrane to a sub-RPE/retinal location. 
Clinically this appears as a greyish-green elevated lesion 
with associated leakage of blood (haemorrhage) and/
or exudation (figure 5). The CNV grows and ultimately 
forms a central scar. Definitive diagnosis is achieved with 
intravenous fluorescein angiography. This defines the size 
and location of the lesion and any associated pigment 
epithelial detachment. Although invasive, the test is quick 
and quite harmless; apart from the remote possibility of 
allergy to the fluorescein dye. It is done on an out-patient 
basis and is also useful in follow-up after treatment.
Until recently treatment of neovascular AMD was not 
very effective in controlling the disease and preventing loss 
of vision. Previous treatments, now less commonly used, 
include: 
•	 Laser treatment to ablate compact lesions away from 
the centre of the macula. This also destroys some 
surrounding healthy tissue leading to a blind spot.
•	 Photodynamic therapy which involves the intravenous 
injection of a drug, verteporfin, which selectively binds 
to growing new vessels in the eye. A specific laser is 
then shined into the eye to activate the drug which 
then causes the blood vessels to close off and regress.
With the introduction of Anti-VEGF injection therapy 
there is now hope in a previously hopeless situation. In 
neovascular AMD, abnormally high levels of vascular 
endothelial growth factor (VEGF) are secreted. This 
protein promotes the growth of abnormal new blood 
vessels. Anti-VEGF agents bind VEGF causing regression 
of the new vessels. This helps stabilise vision and in some 
cases restore some of the vision lost. The agents are injected 
directly into the vitreous of the eye and the injection is 
repeated monthly or bimonthly. The commonly used drugs 
are the approved but expensive ranibizumab (Lucentis®) 
and aflibercept (Eylea®) and the more commonly used 
and cheaper bevacizumab (Avastin®) used off-label. The 
duration of treatment varies in each case and may need 
to be long-term. This treatment is not a cure and the 
condition may progress in spite of this treatment. Ongoing 
stem cell research is beginning to show some promising 
results in the restoration of at least some of the vision lost 
in advanced cases of AMD.  
Figure 2: Early AMD Figure 4: Geographic Atrophy Figure 5: Neovascular AMDFigure 3: Amsler grid chart in advanced AMD
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